|
| 抗BCMA CAR-T细胞治疗复发难治性AQP4-IgG血清阳性视神经脊髓炎谱系疾病的术后管理 |
| Postoperative management after anti BCMA CAR-T cell therapy to treat recurrent and refractory AQP4 IgG seropositive optic neuritis spectrum diseases |
| 投稿时间：2024-10-21 修订日期：2024-10-21 |
| DOI： |
| 中文关键词: 陈黛琪 许艳梅 肖萍 李芳芳 |
| 英文关键词: Chen Daiqi, Xu Yanmei, Xiao Ping, Li Fangfang |
| 基金项目: |
|
| 摘要点击次数: 25 |
| 全文下载次数: 0 |
| 中文摘要: |
| 摘要 目的：本文总结11例复发难治性AQP4-IgG血清阳性视神经脊髓炎谱系疾病患者行抗BCMA CAR-T细胞治疗后神经系统症状的管理经验。方法：对11例抗BCMA CAR-T细胞治疗回输后患者行一般护理观察、细胞因子释放综合征、神经系统症状管理、心理护理、适时康复管理。结果：在中位随访5.5个月(范围1-14个月)期间，11例患者停用所有皮质类固醇和免疫抑制剂后实现无药物缓解均无复发；11例患者报告扩展残疾评定和生活质量的改善。结论：回输后密切观察、早期发现神经系统症状并给予有效管理，减轻患者痛苦，确保抗BCMA CAR-T细胞疗法治疗复发难治性AQP4-IgG血清阳性视神经脊髓炎谱系疾病临床顺利实施。 |
| 英文摘要: |
| Objective: To summarize the experience of 11 patients with relapsed and refractory AQP4-IgG seropositive neuromyelitis optica spectrum disease in the management of neurological symptoms after anti-BCMA CAR-T cell therapy.
Methods: Eleven patients after anti-BCMA CAR-T cell therapy were subjected to general nursing observation, cytokine release syndrome care, neurological symptom management, psychological nursing, and timely rehabilitation management.
Results: During the median follow-up of 5.5 months (range 1-14 months), 11 patients achieved drug-free remission without relapse after discontinuation of all corticosteroids and immunosuppressants; All the patients reported improvements in expanded disability assessment and quality of life.
Conclusions: Close observation after reinfusion, early detection of neurological symptoms and effective management can alleviate the pain of patients and ensure the clinical implementation of anti-BCMA CAR-T cell therapy for the treatment of relapsed and refractory AQP4-IgG seropositive neuromyelitis optica spectrum disease. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |